Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Table: Largest series A financing rounds for companies founded in 2014

    PPPs holding steady Finance Largest series A financing rounds for companies founded in 2014 The largest series A rounds in 2014 went to a pair of cancer T cell immunotherapy companies, with Juno Therapeutics Inc. (…

    Published on 2/5/2015
  • Table: Leaders in the number of public-private partnerships

    PPPs holding steady Finance Leaders in the number of public-private partnerships The National Institutes of Health (NIH) and University of California system took the top positions with respect to the number of …

    Published on 2/5/2015
  • Table: Origins of venture-backed start-ups founded in 2014

    PPPs holding steady Finance Origins of venture-backed start-ups founded in 2014 Venture-backed start-ups founded last year and their scientific origins. Origin is based on the organization that launched the start-…

    Published on 2/5/2015
  • Table: Top public-private partnerships in 2014 by value

    PPPs holding steady Finance Top public-private partnerships in 2014 by value Public-private partnerships (PPPs) that include grants, awards and/or other types of direct funding support from governments and …

    Published on 2/5/2015
  • Strategy: PD-1 matchmaking

    Courting combinations with PD-1

    A host of new targets in the tumor microenvironment could lead to combo therapies that turbo-boost PD-1 mAbs and expand their use, but matching targets and tumors will be the next challenge.

    Published on 1/29/2015
  • Figure: A cohort of co-inhibitors

    PD-1 matchmaking Strategy A cohort of co-inhibitors T cells in the tumor microenvironment express a range of co-inhibitor — or checkpoint — proteins that suppress T cell activity and block their antitumor effects. …

    Published on 1/29/2015
  • Table: Co-inhibitory and co-stimulatory targets

    PD-1 matchmaking Strategy Co-inhibitory and co-stimulatory targets Therapeutics targeting new co-inhibitory and co-stimulatory targets being explored as monotherapies or in combination with other co-inhibitory …

    Published on 1/29/2015
  • Targets & Mechanisms: Unearthing antibiotics

    New antimicrobial peptides from soil bacteria

    Two new techniques for exploiting soil bacteria to find antibiotics have uncovered compound classes and targets that could impact the field even more than the pair of antimicrobials discovered.

    Published on 1/22/2015
  • Box: Dirt Silk Road

    Unearthing antibiotics Targets & Mechanisms Dirt silk road Historically, soil-based bacteria were routinely mined for antibiotics, but the practice has lost ground to synthetic approaches involving structure-based …

    Published on 1/22/2015
  • Tools & Techniques: The right culture

    Mandating cell line validation addresses irreproducibility but poses challenges

    Stakeholders agree that mandating new methods to authenticate cell lines can improve reproducibility in research, but they don't agree on who should lead the charge.

    Published on 1/15/2015
  • Box: Journals take on reproducibility

    The right culture Tools & Techniques Journals take on reproducibility While any one journal cannot single-handedly mandate best practices to the entire research community, together they can promote consensus …

    Published on 1/15/2015
  • Strategy: Plenty of CRISPR pie

    Complex CRISPR IP may have little impact on therapeutic development

    The long term winners in the CRISPR space may have little to do with the impending IP brawl over the technology's inventorship

    Published on 1/8/2015
  • Figure: CRISPR burst

    Plenty of CRISPR pie Strategy CRISPR burst A burst of patent applications in 2014 and dramatic rise in publications related to therapeutic use of CRISPR has followed the publication in 2012 and early 2013 of the …

    Published on 1/8/2015
  • Figure 1: siRNA delivery free of charge

    Cover Story: Neutralizing the negatives of RNAi Figure 1. siRNA delivery free of charge. Short interfering ribonucleic neutrals (siRNNs) are a class of RNAi prodrugs that solve the delivery limitations of standard …

    Published on 12/18/2014
  • Figure: siRNA delivery free of charge

    Neutralizing the negatives of RNAi siRNA delivery free of charge Short interfering ribonucleic neutrals (siRNNs) are a class of RNAi prodrugs that solve the delivery limitations of standard siRNAs and enable …

    Published on 12/18/2014
  • Tools & Techniques: Neutralizing the negatives of RNAi

    siRNN technology delivers RNAi to liver and other tissues

    The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside of the liver and expand their use to a host of new diseases

    Published on 12/18/2014
  • Universal reversal for heparin

    A synthetic, universal heparin reversal agent could provide a lower-risk option for preventing bleeding during surgery than protamine, the standard of care, but finding industry partners could be the challenge.

    Published on 12/11/2014
  • Figure 1: Structure of synthetic UHRAs

    Cover Story: Universal reversal for heparin Figure 1. Structure of synthetic UHRAs. Researchers from The University of British Columbia have developed synthetic dendrimer polymers as universal heparin reversal agents…

    Published on 12/11/2014
  • Figure 1: Solving a family problem

    Cover Story: GPCRs' grand plans Figure 1. Solving a family problem. The GPCR Consortium aims to solve at least 200 unknown structures of GPCRs. The GPCR superfamily contains 826 members, identified based on sequence…

    Published on 12/4/2014
  • GPCRs' grand plans

    A public-private precompetitive consortium aims to expand the number of known GPCR structures from 26 to over 200.

    Published on 12/4/2014
  • Tapping TOPK

    OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds.

    Published on 11/20/2014
  • Table 1: Adjuvant discovery contracts

    Cover Story: Boosting adjuvants Table 1. Adjuvant discovery contracts. The NIH has awarded contracts totaling more than $70 million for 7 new adjuvant discovery projects. Amounts shown represent the potential …

    Published on 11/13/2014
  • Table 2: Selected adjuvants and adjuvanted vaccines for infectious disease

    Cover Story: Boosting adjuvants Table 2. Selected adjuvants and adjuvanted vaccines for infectious disease. Although many marketed vaccines for infectious diseases use alum as an adjuvant, there are three marketed …

    Published on 11/13/2014
  • Boosting adjuvants

    The NIH is committing $70 million to creating new adjuvants that can work with different types of vaccines and wants industry to get involved.

    Published on 11/13/2014
  • A conversation with Elias Zerhouni

    Sanofi's Elias Zerhouni wants a dedicated national fund to keep young scientists involved in research, which he thinks should be the top policy priority for advancing biomedical innovation.

    Published on 11/6/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993